Oppenheimer analyst Jeff Jones lowered the firm’s price target on Chemomab Therapeutics (CMMB) to $10 from $11 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 financial results, highlighting recent updates, including regulatory feedback providing clear guidance on approvable endpoints for nebokitug in PSC, and recent positive 48 weeks SPRING OLE results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab Therapeutics Advances Nebokitug Towards Phase 3 After Positive Trial Results
- Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year
- Chemomab Therapeutics: Promising Phase 2 Data and Attractive Entry Point Justify Buy Rating
- Chemomab Therapeutics announces presentation of Phase 2 data of CM-101
- Biotech Alert: Searches spiking for these stocks today